Travere Therapeutics, Inc.

Industry

  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Nasal

Other Names/Subsidiaries

  • Desert Gateway
  • Kyalin Biosciences
  • Manchester Pharmaceuticals
  • Orphan Technologies
  • Retrophin
  • Manchester Pharmaceuticals
See more in Biomedtracker

Latest on Travere Therapeutics, Inc.

Scrip

Vanrafia Approval Plays Into Novartis’s Multipronged IgAN Approach

 
• By Alaric DeArment and Andrew McConaghie

Although Novartis’s immunoglobulin A nephropathy (IgAN) franchise will face considerable competition from other firms, the accelerated approval in the US of Vanrafia (atrasentan) further solidifies it

Scrip

IgAN Market Snapshot: Growing Market, But Patient Segmentation Still A Question

 
• By Alaric DeArment

In the space of only a few years, immunoglobulin A nephropathy (IgAN) has gone from no drug therapies available to three options on a list that is growing. The questions that remain now are how to seg

Pink Sheet

Metabolic And Endocrine Therapies Could Star Among US FDA’s Last 2024 Approvals

 
• By Bridget Silverman

US Food and Drug Administration approval decisions for endocrine and metabolic disease therapies will crescendo through the rest of 2024, and could briefly make more noise than the perpetually dominan

Scrip

Finance Watch: Biopharma Stocks Sink On RFK Jr. Nomination To Head HHS

 
• By Mandy Jackson

President-elect Donald Trump’s plan to nominate Robert F. Kennedy Jr. as secretary of the US Department of Health and Human Services was not entirely unexpected, but it sent biopharmaceutical stock va